Literature DB >> 15721725

Postoperative outcome of patients with narcolepsy. A retrospective analysis.

Bethanie Burrow1, Christopher Burkle, David O Warner, Eduardo N Chini.   

Abstract

STUDY
OBJECTIVE: To determine the postoperative outcome of narcolepsy patients, a population that may be at increased risk of perioperative complications, including postoperative hypersomnia, prolonged emergence after general anesthesia, and apnea.
DESIGN: Retrospective chart review.
SETTING: Academic medical center. MEASUREMENTS: The perioperative outcome of pharmacologically treated narcolepsy patients, diagnosed at the Mayo Clinic sleep laboratory between January 1, 1965, and December 31, 2001, was studied. A total of 37 narcolepsy patients was identified. Charts were reviewed for the following perioperative (intraoperative time plus recovery room time) events: time for extubation, duration of stay in the Postanesthesia Care Unit (PACU), and duration of stay in the hospital. Furthermore, any of the following complications were noted: electrocardiographic (ECG) changes, postoperative nausea and vomiting, hypotension, subjective reports of pain, decreasing oxygen saturation (SpO(2)) levels, respiratory complications, postoperative fever, agitation in the PACU, and hypersomnolence in PACU. In addition, patient hospital stay and major morbidity and mortality during hospital stay were recorded. MAIN
RESULTS: Ten patients pharmacologically treated for their narcolepsy symptoms that underwent 27 noncardiac surgical procedures under general anesthesia. We found no evidence that the pharmacologically treated narcolepsy patients were at any increased risk for perioperative complications. Furthermore, their time for endotracheal extubation, length of stay in the PACU and hospital did not differ from nonnarcolepsy patients.
CONCLUSION: Pharmacological therapy for narcolepsy should be continued during the perioperative period. In addition, treated narcolepsy patients are at no increased risk for postoperative complications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721725     DOI: 10.1016/j.jclinane.2004.03.007

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  7 in total

1.  An essential role for orexins in emergence from general anesthesia.

Authors:  Max B Kelz; Yi Sun; Jingqiu Chen; Qing Cheng Meng; Jason T Moore; Sigrid C Veasey; Shelley Dixon; Marcus Thornton; Hiromasa Funato; Masashi Yanagisawa
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

Review 2.  Escape From Oblivion: Neural Mechanisms of Emergence From General Anesthesia.

Authors:  Max B Kelz; Paul S García; George A Mashour; Ken Solt
Journal:  Anesth Analg       Date:  2019-04       Impact factor: 5.108

3.  Anesthetic management of a patient with narcolepsy.

Authors:  Yasuhiro Morimoto; Yuko Nogami; Kaori Harada; Hiroko Shiramoto; Takayo Moguchi
Journal:  J Anesth       Date:  2011-03-30       Impact factor: 2.078

4.  A conserved behavioral state barrier impedes transitions between anesthetic-induced unconsciousness and wakefulness: evidence for neural inertia.

Authors:  Eliot B Friedman; Yi Sun; Jason T Moore; Hsiao-Tung Hung; Qing Cheng Meng; Priyan Perera; William J Joiner; Steven A Thomas; Roderic G Eckenhoff; Amita Sehgal; Max B Kelz
Journal:  PLoS One       Date:  2010-07-30       Impact factor: 3.240

5.  Anesthetic management of a patient with narcolepsy for emergency caesarean section.

Authors:  Mehtap Honca; Merve Bayraktaroglu; Eyup Horasanli
Journal:  Korean J Anesthesiol       Date:  2013-12

6.  Total Intravenous Anesthesia for Neurosurgical Procedures in Narcoleptic Patients: Two Case Reports.

Authors:  Sara Pedrosa; Nuno Lareiro; Pedro Amorim
Journal:  Anesth Pain Med       Date:  2017-05-07

7.  Central Disorders of Hypersomnolence, Restless Legs Syndrome, and Surgery With General Anesthesia: Patient Perceptions.

Authors:  Vincent LaBarbera; Paul S García; Donald L Bliwise; Lynn M Trotti
Journal:  Front Hum Neurosci       Date:  2018-03-20       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.